ALK-Positive Lung Cancer: Why a Genomic Report May Still Need a Second Opinion
Direct answer: an ALK-positive result is important, but it does not by itself determine the complete treatment plan. The result still has to be interpreted alongside pathology, the testing method, disease stage, previous ALK inhibitors, treatment response, adverse effects and the pattern of progression.
Why the report is only the starting point
Patients and families may receive a report showing an ALK fusion and understandably assume that choosing an ALK inhibitor is the only remaining decision. In practice, several questions can materially change the next step:
- Was the tumour diagnosis and subtype confirmed?
- Was the tissue sample adequate, and which method detected the fusion?
- Do tissue and blood-based results agree?
- Is this first-line treatment or progression after an earlier ALK inhibitor?
- Is progression widespread or limited to a small number of lesions?
- Are brain metastases present, stable or progressing?
A negative liquid-biopsy result does not always exclude an ALK fusion because the amount of circulating tumour DNA may be insufficient. Conversely, a positive result still requires clinical interpretation before treatment is changed.
What a specialist second opinion may review
A useful second opinion should not simply recommend a newer medicine. It may review the original pathology, imaging, complete genomic report and treatment timeline to answer whether the current plan is logically supported.
For patients whose disease has progressed, the specialist may consider whether repeat tissue sampling or another molecular test could clarify a resistance mechanism. Progression in one or a few sites may also raise a different question from widespread progression: whether local treatment, such as stereotactic radiotherapy, should be discussed while systemic therapy is reassessed.
Brain metastases require particular care. Their size, number, symptoms, previous radiation and the central nervous system activity of the current drug all influence whether the next discussion concerns systemic treatment, focused radiation or another multidisciplinary strategy.
Who may benefit most
A second opinion may be especially useful when testing methods disagree, different hospitals recommend different treatment sequences, progression occurs during targeted therapy, brain metastases complicate the decision, or a rare fusion pattern is reported.
It may be less urgent when the diagnosis and treatment plan are clear and the disease is responding as expected. Patients with acute breathing difficulty, altered consciousness or another emergency should seek immediate local medical care rather than wait for an overseas opinion.
Documents commonly needed
- Pathology report and, when requested, slides or digital pathology files
- The complete genomic test report, not only the summary page
- Original CT, MRI or PET imaging in DICOM format
- A chronological record of surgery, radiation and systemic treatments
- Drug names, doses, dates, response assessments and adverse effects
- Recent laboratory results and current symptoms
- Three to five specific questions for the reviewing specialist
Frequently asked questions
Does an ALK-positive result automatically mean one particular drug should be used?
No. Eligibility and treatment order depend on the approved indication, previous therapy, disease distribution, health status and specialist judgement.
Is a genomic panel a treatment?
No. It is a diagnostic tool. A detected alteration is not the same as a guaranteed treatment opportunity.
Will a Japanese second opinion overturn the original plan?
Not necessarily. It may confirm the current plan, identify missing information or describe reasonable alternatives.
Does obtaining a Japanese opinion require travel to Japan?
No. A written second opinion is first a decision-support tool. Many recommendations can be discussed with the treating team in the patient’s home country.
Evidence and source note
This educational article is based on official information from Chugai Pharmaceutical concerning the September 2026 Japanese approval of FoundationOne CDx as a companion diagnostic for lorlatinib in ALK fusion-positive non-small cell lung cancer, together with general cancer genomic medicine information from Japan’s National Cancer Center.
Japan Expert Second Opinion: A second opinion is intended to support medical decision-making. It does not guarantee a different diagnosis, a new treatment option or a better outcome, and it does not mean that the patient must travel to Japan.
This article is for general education and does not provide an individual diagnosis or treatment recommendation.
微信公众号 / WeChat Official Account：德川在东京
更多日本医疗、癌症专家第二意见与精准医疗原创内容，请关注公众号“德川在东京”。
For more original content on Japanese medical care and expert second opinions, follow “德川在东京” on WeChat.